Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Boadilla Del Monte – page 49

3 267 clinical trials in Boadilla Del Monte, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Boadilla Del Monte at a glance
3 267
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 267 trials in Boadilla Del Monte

Open in trial search

Plasma cell myeloma

Recruiting

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Neoplasm malignant

Recruiting

Study of BMS-986504 for patients with advanced or metastatic non-small cell lung cancer with homozygous MTAP deletion who have previously received treatment

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Navlimetostat
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Respiratory syncytial virus infection

Recruiting

Study of RSV vaccine immune response persistence and revaccination safety in adult lung and kidney transplant recipients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:GlaxoSmithKline Biologicals

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Colorectal cancer

Recruiting

Study of ONO-4578 and nivolumab with drug combination for first-line treatment in patients with PD-L1 positive advanced colorectal cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Ono Pharmaceutical Co. Ltd.

Endometrial cancer+2

Recruiting

Study of MK-5684 compared to standard therapy in patients with breast cancer, ovarian cancer, or endometrial cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Exemestane
  • Sponsor:Merck Sharp & Dohme LLC

Colorectal cancer metastatic

Recruiting

Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione GONO G.I.

Major depression

Recruiting

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Osavampator
  • Sponsor:Neurocrine Biosciences Inc.

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Transitional cell cancer of the renal pelvis and ureter

Recruiting

Study of UGN-104 (mitomycin) treatment for patients with low-grade upper tract urothelial cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.

Desmoplastic small round cell tumour

Recruiting

Study of lurbinectedin and irinotecan in adults and young adults with advanced desmoplastic small round cell tumor

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lurbinectedin
  • Sponsor:Italian Sarcoma Group

Dermatitis atopic

Recruiting

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:GHZ339
  • Sponsor:Novartis Pharma AG

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Boadilla Del Monte

What the registry says about research in the country

01 Infectious Disease Prevention

Clinical trials focusing on vaccine development and immune responses for multiple infectious diseases, including studies of combination vaccines for childhood diseases and COVID-19 boosters.

  • MMRV Vaccine Studies
  • COVID-19 Booster Research
  • RSV Prevention

Special emphasis on pediatric populations and vaccine co-administration safety protocols.

02 Oncology Research

Comprehensive studies on various cancer types, with focus on pediatric liver cancers and innovative treatment approaches for solid tumors.

  • Hepatoblastoma Treatment
  • High-Grade Glioma Therapy
  • Prostate Cancer Management

Integration of targeted therapies and combination treatment protocols.

03 Cardiovascular Medicine

Investigations into cardiovascular disease prevention and treatment, particularly focusing on post-heart attack care and preventive measures.

  • ASCVD Prevention
  • Acute Coronary Syndrome
  • Cardiovascular Risk Management

Emphasis on long-term cardiovascular outcomes and preventive strategies.

04 Women's Health

Studies examining reproductive health and related conditions, including contraceptive efficacy and treatments for gynecological infections.

  • Contraceptive Development
  • Vaginal Health Studies
  • Treatment of Candidiasis

Focus on innovative delivery systems and treatment options.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.